Please note, unless the presenters give permission to have their presentations recorded, the live-stream presentation will only be viewable during the listed time.
Thank you for your understanding.
Dr. Jeremie Calais is Assistant Professor and Director of the Clinical Research Program of the Ahmanson Translational Theranostics Division of the Department of Molecular and Medical Pharmacology at UCLA and is one of the leading prostate cancer imaging and theranostics researchers
Update 2021 - Imaging based prostate cancer management
BERNADETTE GREENWOOD MSC., PG CERT., RT(R)(MR)(ARRT) CHIEF RESEARCH OFFICER AT HALODX CLINICAL INSTRUCTOR, DEPARTMENT OF INTERNAL MEDICINE UC RIVERSIDE SCHOOL OF MEDICINE.
Bernadette gave an update on oncologic imaging and prostate MRI and MR-guided intervention.
Read her Bio here
Dr. Schwartzberg will be discussing the rationale for deleting gadolinium contrast sequence asroutine part of multiparametric prostate mri. The Dr. will also touch on the ongoing issues of quality of images and quality of interpretation in the community.
Bernadette Greenwood – Desert Medical Imaging -- Imaging and Genomics in Prostate Cancer Management. She has a BS in radiologic sciences, earned a postgraduate Certificate in Imaging Sciences from University of Edinburgh and is working on a Ph.D. in tumor immunology imaging. Many awards and publications.
The main areas Bernadette covers are:
1. The history of biopsy strategies
2. Technical aspects of MRI imaging
3. Rationale for her early work (2008-2009) on development and use of MRI-guided laser focal therapy of PCa
4. Update on NCT #02243033 (Phase II clinical trial of laser focal therapy)
5. PET (positron emission tomography) imaging with Axumin imaging agent
6. Potential role of genomic classifiers for risk stratification
Dr. Paul Dato is a urologist and currently serves as Director for Medical Quality and Director of the Prostate Cancer Center for Genesis healthcare. Dr. Dato discussed Active Surveilance, what it is and where we are at today with utilizing this form of Prostate Cancer monitoring.
Dr. A.J. Mundt assembled a fantastic panel for the first IPCSG Webinar of 2021. Below is the list of speakers and an overview of their presentations. (Following the presentations audiance questions were answered)
GENETIC TESTING IN PROSTATE CANCER
A double board-certified internist and oncologist, Richard Lam, MD, has been specializing full time at Prostate Oncology Specialists in the treatment of prostate cancer since 2001.
Dr. Lam discussed genetic testing and how it's being applied for prostate cancer research, diagnosis and treatment.
As always, his presentations was very informative and presented in an easily understood format. He also brought a great wit with a touch of humor.
Dr.Carl Rossi and Dr. Einck
Advances in Proton Therapy
Carl Rossi, MD, radiation oncologist and Medical Director of the California Proton Treatment Center has personally treated more than 10,000 prostate cancer patients with proton radiation over the last 26 years—more than any other physician in the world.
John P. Einck, MD, Radiation Oncologist and Professor of Radiation Medicine and Applied Sciences believes in a team-based approach to patient care. Dr. Einck joined California Protons Cancer shortly after the center’s opening in 2014. His treatment philosophy emphasizes patient education and encourages everyone to participate in deciding what course of treatment is best for them and their personal goals.
Dr. Sumit Subudhi is a medical oncologist and immunologist whose research focuses on the mechanisms and pathways within the immune system that are responsible for tumor rejection.
Dr. Subudhi’s work includes examining the effects of targeting immune checkpoints (e.g., CTLA-4 and PD-1) in prostate cancer and continuing to uncover the mechanisms that tumors use to evade the immune system.
Due to COVID-19, no in-person meetings will be held at the Sanford Burnham Prebys Medical Discovery Institute until further notice.